Knight Therapeutics’ Acquisition of remaining 48,79 % in Biotoscana


Davies Ward Phillips & Vineberg, Pinheiro Neto, Bonn Steichen & Partners and Lobo de Rizzo advised on the transaction

Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. completed the tender offer process filed by 1178991 CANADA INC. for the acquisition and delisting of all outstanding Brazilian Depositary Receipts of Biotoscana Investments S.A.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pan-American (ex-US) specialty pharmaceutical company focused on developing, acquiring or in-licensing and commercializing innovative pharmaceutical products for Canada and Latin America. Knight owns a controlling stake in Grupo Biotoscana, a pan-Latin American specialty pharmaceutical company.

Davies Ward Phillips & Vineberg advised Knight Therapeutics Inc. with Hillel W. Rosen (Picture), Brian Kujavsky, Shayna Goldman and Julia Knafo.

In Brazil, Pinheiro Neto advised Knight Therapeutics Inc. with Guilherme Sampaio Monteiro, Milena Casado de Oliveira, Marcelo Junqueira de Mello, Taisa Sani and Letícia Fonseca Marcondes Venancio.

Bonn Steichen & Partners advised Advent International and Essex Woodlands.

In Brazil, Lobo de Rizzo Advogados advised Advent International and Essex Woodlands

Involved fees earner: Shayna Goldman – Davies Ward Philips & Vineberg; Julia Knafo – Davies Ward Philips & Vineberg; Brian Kujavsky – Davies Ward Philips & Vineberg; Hillel Rosen – Davies Ward Philips & Vineberg; Milena Casado de Oliveira – Pinheiro Neto; Marcelo Junqueira de Mello – Pinheiro Neto; Guilherme Sampaio Monteiro – Pinheiro Neto; Taisa Sani – Pinheiro Neto;

Law Firms: Davies Ward Philips & Vineberg; Pinheiro Neto;

Clients: Knight Therapeutics Inc. ;

Author: Ambrogio Visconti